Lukkahatai, N.; Park, J.; Jia, H.M.; Martin, D.; Li, J.; Sheng, J.Y.-S.; Gill, J.; Saligan, L.N.; Stearns, V.; Carducci, M.
Feasibility of DNA Methylation Age as a Biomarker of Symptoms and Resilience among Cancer Survivors with Multiple Chronic Conditions. Biomedicines 2023, 11, 3076.
https://doi.org/10.3390/biomedicines11113076
AMA Style
Lukkahatai N, Park J, Jia HM, Martin D, Li J, Sheng JY-S, Gill J, Saligan LN, Stearns V, Carducci M.
Feasibility of DNA Methylation Age as a Biomarker of Symptoms and Resilience among Cancer Survivors with Multiple Chronic Conditions. Biomedicines. 2023; 11(11):3076.
https://doi.org/10.3390/biomedicines11113076
Chicago/Turabian Style
Lukkahatai, Nada, Jongmin Park, Hejingzi Monica Jia, Daniel Martin, Junxin Li, Jennifer Yeong-Shin Sheng, Jessica Gill, Leorey N. Saligan, Vered Stearns, and Michael Carducci.
2023. "Feasibility of DNA Methylation Age as a Biomarker of Symptoms and Resilience among Cancer Survivors with Multiple Chronic Conditions" Biomedicines 11, no. 11: 3076.
https://doi.org/10.3390/biomedicines11113076
APA Style
Lukkahatai, N., Park, J., Jia, H. M., Martin, D., Li, J., Sheng, J. Y.-S., Gill, J., Saligan, L. N., Stearns, V., & Carducci, M.
(2023). Feasibility of DNA Methylation Age as a Biomarker of Symptoms and Resilience among Cancer Survivors with Multiple Chronic Conditions. Biomedicines, 11(11), 3076.
https://doi.org/10.3390/biomedicines11113076
